Compare ALNY & UAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNY | UAL |
|---|---|---|
| Founded | 2002 | 1934 |
| Country | United States | United States |
| Employees | 115 | 87000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.1B | 35.9B |
| IPO Year | 2004 | 1995 |
| Metric | ALNY | UAL |
|---|---|---|
| Price | $308.66 | $93.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 29 | 17 |
| Target Price | ★ $467.68 | $129.75 |
| AVG Volume (30 Days) | 913.6K | ★ 7.4M |
| Earning Date | 04-30-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 206.88 | 7.94 |
| EPS | 2.33 | ★ 10.20 |
| Revenue | $1,037,418,000.00 | ★ $37,736,000,000.00 |
| Revenue This Year | $53.50 | $9.97 |
| Revenue Next Year | $32.29 | $6.11 |
| P/E Ratio | $134.28 | ★ $8.81 |
| Revenue Growth | ★ 22.88 | 3.23 |
| 52 Week Low | $205.87 | $52.00 |
| 52 Week High | $495.55 | $119.21 |
| Indicator | ALNY | UAL |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 43.56 |
| Support Level | $296.91 | $86.92 |
| Resistance Level | $310.00 | $94.01 |
| Average True Range (ATR) | 9.36 | 4.22 |
| MACD | -0.12 | 0.41 |
| Stochastic Oscillator | 26.55 | 59.98 |
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Chicago-based United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel, especially across the Pacific, than its large US peers.